Outcomes of patients with ER+/HER2+non-metastatic breast cancer treated with trastuzumab without chemotherapy

被引：0
|
作者：
Nguy, Susanna [1 ]
Wu, S. Peter [1 ]
Oh, Cheongeun [1 ]
Gerber, Naamit K. [1 ]
机构：
[1] NYU Langone Med Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P1-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-02
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [22] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [23] ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer
    Arciero, Cletus A.
    Guo, Yi
    Jiang, Renjian
    Behera, Madhusmita
    O'Regan, Ruth
    Peng, Limin
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2019, 19 (04) : 236 - 245
  • [24] Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting
    Murthy, Rashmi Krishna
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana J.
    Murray, James L.
    Koenig, Kimberly Higginbotham
    Green, Marjorie C.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Booser, Daniel J.
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Targeting focal adhesion kinase in ER+/HER2+breast cancer improves trastuzumab response
    Lazaro, Glorianne
    Smith, Chris
    Goddard, Lindy
    Jordan, Nicola
    McClelland, Richard
    Barrett-Lee, Peter
    Nicholson, Robert I.
    Hiscox, Stephen
    ENDOCRINE-RELATED CANCER, 2013, 20 (05) : 691 - 704
  • [26] Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2+or HER2-metastatic breast cancer
    Hunter, Natasha
    Peterson, Lanell M.
    Mankoff, David A.
    Muzi, Mark
    Chen, Delphine
    Gwin, William R.
    Vinayak, Shaveta
    Davidson, Nancy E.
    Specht, Jennifer M.
    Linden, Hannah
    CANCER RESEARCH, 2023, 83 (05)
  • [27] Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2-Advanced/Metastatic Breast Cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Tokuda, Toshiki
    Kaburagi, Takuji
    Okumura, Takehiro
    Karahashi, Tsuyoshi
    Nakajima, Kenichiro
    Higeta, Kaori
    Shimizu, Ken
    IN VIVO, 2019, 33 (06): : 2037 - 2044
  • [28] Efficacy and safety of everolimus for heavily pretreated patients with ER+/HER2-metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Fujisue, Mamiko
    Yamada, Mitsuhiro
    Suko, Kyoko
    Morioka, Junko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] BUDGET IMPACT ANALYSIS OF EVEROLIMUS FOR ER+, HER2-METASTATIC BREAST CANCER PATIENTS IN THE UNITED STATES
    Xie, J.
    Diener, M.
    De, G.
    Wu, E. Q.
    Namjoshi, M.
    VALUE IN HEALTH, 2012, 15 (04) : A212 - A212
  • [30] Treatment patterns and clinical outcomes in ER+/HER2-metastatic breast cancer in German real world settings
    Mitra, D.
    Kurosky, S.
    Kaye, J.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S141 - S141
12345